7 reports

Datamonitor Healthcare Strategy: Gene Therapy Commercialization – Opportunities and Barriers CONTENTS ## OVERVIEW ## APPROVED GENE THERAPY LANDSCAPE ## Datamonitor Healthcare insights and recommendations ## Gene therapy: a field in existence for ## years, but setbacks have

  • Biopharmaceutical
  • Gene Therapy
  • Medical Biotechnology
  • United States
  • Supply
  • 124 VIVEBIOTECH
  • 124 VIVEBIOTECH

ONE OF THE KEY GROWTH DRIVERS IS THE PIPELINE OF APPROVED AND CLINICAL GENE THERAPY CANDIDATES.

  • Gene Therapy
  • United States
  • Supply
  • Lonza Group Ltd
  • Sanofi S.A.
  • GENE THERAPIES, GLOBAL, PRODUCTION OF VIRAL VECTORS FOR GENE THERAPY; GENOME
  • GENE THERAPIES, GLOBAL, VIRAL GENE THERAPY VECTOR MANUFACTURE; GENERAL

Human Gene Therapy Methods; ##(##): ##-## Wright J (2014).

  • Biopharmaceutical
  • Gene Therapy
  • Medical Biotechnology
  • Therapy
  • Supply
  • Apr 18, 2017: Cobra Biologics Embarks On £15m (165m SEK) Gene Therapy Manufacturing Operations Expansion
  • Cobra Biologics Partners with Touchlight Genetics

The company offers its development services for viral gene therapy, cell therapy, mRNA, gene editing, monoclonal antibodies, non-viral gene therapy.

  • Gene Therapy
  • Medical Biotechnology
  • Pharmaceutical
  • United Kingdom
  • Supply

The first patient is likely to receive the novel gene therapy in late H## 2018 and we anticipate data from the cohort one part of the study within one year.

  • Gene Therapy
  • Medical Biotechnology
  • United Kingdom
  • Supply
  • Oxford BioMedica plc

CAR has become one of the most promising innovative therapeutic strategies in oncology.

  • Gene Therapy
  • Europe
  • Italy
  • Supply
  • MolMed S.p.A.
  • Feb 13, 2017: Novasep Invests in a €27m Viral Vector Production Facility

The viral vectors are used in gene therapies or immunotherapies such as new cancer treatment strategies and in " new generation" therapeutic vaccines.

  • Gene Therapy
  • Pharmaceutical
  • United States
  • Supply
  • Repligen Corporation